About EYLEA and Wet Age-related Macular Degeneration About EYLEA and Wet Age-related Macular Degeneration

EYLEA &
Wet AMD

Learn more about EYLEA, the #1 prescribed FDA-approved anti-vascular endothelial growth factor treatment for patients with Wet Age-related Macular Degeneration (Wet AMD).

ABOUT EYLEA

EYLEA has been studied in more than 3,000 people with certain diseases of the retina.

EYLEA is a prescription medicine given by injection into the eye. You should not use EYLEA if you have an infection in or around the eye, eye pain or redness, or known allergies to any of the ingredients in EYLEA, including aflibercept.

HOW EYLEA WORKS

EYLEA is an anti-vascular
endothelial growth factor
(anti-VEGF) treatment that is given by injection into the eye and works by blocking VEGF. EYLEA blocks VEGF by trapping it between its molecular arms.

Anti-vascular endothelial growth factor (anti-VEGF) treatment

WHAT IS VEGF

People with Wet AMD have high amounts of VEGF (a type of protein that affects blood vessels). At high levels, VEGF can cause blood vessels to leak fluid and also result in the growth of abnormal blood vessels. This damages the macula and can lead to vision loss.

Vision improvements seen with EYLEA

In 2 clinical studies, 1,815 people with Wet AMD received injections of EYLEA (2 mg) either once every 8 weeks after 3 initial monthly doses or once every 4 weeks or ranibizumab once every 4 weeks.

Both studies measured the percentage of people whose vision was maintained (not losing 15 or more letters, or 3 lines, on the eye chart) at 1 year.

9 out of 10 patients treated with EYLEA maintained their vision at 1 year.

Of people treated with EYLEA in the 2 clinical studies at 1 year, 9 out of 10 maintained their vision at 1 year.

Eye chart before EYLEA anti-VEGF.
Letters gained on eye chart after EYLEA anti-VEGF measured at 1 year.

On average, at one year, people treated with EYLEA in the studies gained at least 7 more letters on the eye chart than before treatment.

Results from the clinical studies were seen with an average of 7 to 8 treatments of EYLEA 2 mg dosed every 8 weeks (following 3 initial monthly doses) through 1 year.

These results are from 2 clinical studies; your individual results may vary. Discuss with your eye care team what treatment schedule with EYLEA may be right for you.

Recommended dosing

IT'S IMPORTANT TO KEEP UP WITH YOUR TREATMENT SCHEDULE

EYLEA is the only FDA-approved treatment for Wet AMD with a recommended dose of 2 mg administered by injection in the eye every 4 weeks (approximately every 28 days, monthly) for the first 3 months, followed by injection once every 8 weeks (2 months). EYLEA may be dosed once per month, but in most patients, additional benefit was not seen with this dosing plan. Some patients may need every 4 week (monthly) dosing after the first 12 weeks (3 months). Although not as effective, patients may also be treated with 1 dose every 12 weeks after 1 year of effective treatment. Patients who have this dosing schedule should have their vision checked regularly. Your eye care team will determine the EYLEA dosing schedule that's right for you.

Your eye care team will want to see you regularly to check your vision and also check your treatment progress with EYLEA. Work with your eye care team to make sure you can keep your appointments and stay on your recommended treatment schedule.

Safety information for EYLEA

EYLEA® (aflibercept) Injection is a prescription medicine administered by injection into the eye. You should not use EYLEA if you have an infection in or around the eye, eye pain or redness, or known allergies to any of the ingredients in EYLEA, including aflibercept.

Injection into the eye with EYLEA can result in an infection in the eye and retinal detachment (separation of retina from back of the eye). Inflammation in the eye has been reported with the use of EYLEA.

In some patients, injections with EYLEA may cause a temporary increase in eye pressure within 1 hour of the injection. Sustained increases in eye pressure have been reported with repeated injections, and your doctor may monitor this after each injection.

There is a potential risk of serious and sometimes fatal side effects related to blood clots, leading to heart attack or stroke in patients receiving EYLEA.

Serious side effects related to the injection procedure with EYLEA are rare but can occur including infection inside the eye and retinal detachment.

The most common side effects reported in patients receiving EYLEA are increased redness in the eye, eye pain, cataract, vitreous (gel-like substance) detachment, moving spots in the field of vision, and increased pressure in the eye.

As with all therapeutic proteins, there is a potential for an immune response in patients treated with EYLEA.

It is important that you contact your doctor right away if you think you might be experiencing any side effects, including eye pain or redness, light sensitivity, or blurring of vision, after an injection.

FINANCIAL SUPPORT FROM EYLEA4U®

MONITORING YOUR VISION IS IMPORTANT

EYLEA4U® logo

EYLEA4U is a comprehensive support program with several resources available to help eligible patients with the cost of EYLEA.

Learn about vision tests.

Learn about some of the tests your doctor may use to diagnose and monitor your condition, and what you can do at home.

IMPORTANT SAFETY INFORMATION
  • EYLEA® (aflibercept) Injection is a prescription medicine administered by injection into the eye. You should not use EYLEA if you have an infection in or around the eye, eye pain or redness, or known allergies to any of the ingredients in EYLEA, including aflibercept.
  • Injection into the eye with EYLEA can result in an infection in the eye and retinal detachment (separation of retina from back of the eye). Inflammation in the eye has been reported with the use of EYLEA.
  • In some patients, injections with EYLEA may cause a temporary increase in eye pressure within 1 hour of the injection. Sustained increases in eye pressure have been reported with repeated injections, and your doctor may monitor this after each injection.
  • There is a potential risk of serious and sometimes fatal side effects related to blood clots, leading to heart attack or stroke in patients receiving EYLEA.
  • Serious side effects related to the injection procedure with EYLEA are rare but can occur including infection inside the eye and retinal detachment.
  • The most common side effects reported in patients receiving EYLEA are increased redness in the eye, eye pain, cataract, vitreous (gel-like substance) detachment, moving spots in the field of vision, and increased pressure in the eye.
  • It is important that you contact your doctor right away if you think you might be experiencing any side effects, including eye pain or redness, light sensitivity, or blurring of vision, after an injection.
  • EYLEA is for prescription use only. For additional safety information, please talk to your doctor and see the full Prescribing Information for EYLEA.

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

INDICATIONS

EYLEA® (aflibercept) Injection is a prescription medicine approved for the treatment of patients with Wet Age-related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR) in patients with DME.

Please see the full Prescribing Information for EYLEA.

The information contained herein is provided for general educational purposes. If you have any questions, talk to your doctor.

For U.S. Residents Only

EYLEA AND EYLEA4U are registered trademarks of Regeneron Pharmaceuticals, Inc.

© 2019, Regeneron Pharmaceuticals, Inc. All rights reserved.
777 Old Saw Mill River Road,
Tarrytown, NY 10591

03/2019
US-LEA-14281c(1) US-LEA-14281c(1)

 

Searching with Lea

Close
MENU